Ganesh Kumar Viswanathan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ganesh Kumar Viswanathan has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Jasmita Dass
Department of Hematology, AIIMS, New Delhi, India
18 shared publications - Tulika Seth
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
14 shared publications - Manoranjan Mahapatra
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India
13 shared publications - Mukul Aggarwal
Department of Hematology, AIIMS, New Delhi, India
13 shared publications - Rishi Dhawan
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
10 shared publications - Pradeep Kumar
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
8 shared publications
Latest Publications
- 26 June 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (6) , 283-286
Unresponsive Systemic Mastocytosis in a Young AML With RUNX1::RUNX1T1 Fusion With Rare KIT c.1255_1257delGAC Mutation: A Clinical Deadlock
Background: Systemic mastocytosis (SM) with associated acute myeloid leukemia (AML) is a rare malignancy usually linked to KIT p.D816V mutations. Observation(s): We report a 17-year-old female with RUNX1::RUNX1T1 -positive AML and florid mast cell proliferation harboring a rare KIT exon 8 deletion (p.Asp419del). Diagnosis required integration of morphology, immunophenotyping, and polymerase chain reaction, as routine NGS failed to detect the mutation. Despite remission following intensive chemotherapy and imatinib, the patient developed persistent mastocytosis and succumbed to septic shock. Conclusions: This first reported case of SM-AML with KIT p.Asp419del highlights the need for comprehensive molecular testing and tailored therapy in atypical presentations.
- 26 June 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (6) , 283-286
Unresponsive Systemic Mastocytosis in a Young AML With RUNX1::RUNX1T1 Fusion With Rare KIT c.1255_1257delGAC Mutation: A Clinical Deadlock
Background: Systemic mastocytosis (SM) with associated acute myeloid leukemia (AML) is a rare malignancy usually linked to KIT p.D816V mutations. Observation(s): We report a 17-year-old female with RUNX1::RUNX1T1 -positive AML and florid mast cell proliferation harboring a rare KIT exon 8 deletion (p.Asp419del). Diagnosis required integration of morphology, immunophenotyping, and polymerase chain reaction, as routine NGS failed to detect the mutation. Despite remission following intensive chemotherapy and imatinib, the patient developed persistent mastocytosis and succumbed to septic shock. Conclusions: This first reported case of SM-AML with KIT p.Asp419del highlights the need for comprehensive molecular testing and tailored therapy in atypical presentations.
- Open Access
Integrated Genomic Profiling of Newly Diagnosed and Relapsed Acute Myeloid Leukemia Identifies Driver Genes, Mutational Signatures, and Therapeutic Targets
Background/Objectives: Acute myeloid leukemia (AML) is a hematologic malignancy of substantial genetic heterogeneity that exhibits clonal growth and blocked differentiation of myeloid progenitor cells in the bone marrow (BM). Genetic alterations play a vital role in the progression, initiation, and recurrence of AML. The aim of this study was to identify the somatic mutational landscape, pathway perturbations, mutational signatures, and druggability of baseline (at diagnosis) and relapsed AML to determine possible treatment options. Methods: Between 2020 and 2026, 120 diagnostic BM or PB samples were prospectively collected from baseline (at diagnosis) AML patients at AIIMS, New Delhi. WES was conducted of 10 BM samples from five baseline (at diagnosis) and five relapsed patients with AML. Somatic variations were identified by GATK-Mutect2 and annotated by ANNOVAR. Driver genes and pathways were analyzed using Maftools, OncodriveCLUST, and clusterProfiler. Extraction of mutational signatures was performed with the help of SigProfilerExtractor, and evaluation of drug–gene interactions was carried out with the help of DGIdb. In addition, RT-PCR was performed to estimate the expression level of TET1. The recurrent TET1 variation was validated using Sanger sequencing and PCR amplification. Results: Missense mutations were the most common variant type in the cohort, and C > T transitions were the predominant nucleotide substitution pattern. There were recurrent mutations in core AML driver genes, including TET1, FLT3, and TP53, and relapsed samples demonstrated increased involvement and complexity of the signaling system. Pathway analysis revealed widespread dysregulation of carcinogenic networks, including RTK-RAS, WNT, TP53, and PI3K signaling. Mutational signature analysis identified COSMIC SBS5, SBS8, and SBS40, which are associated with mechanisms involving oxidative damage. A large number of actionable targets were identified through druggability screening, particularly involving epigenetic regulators and kinase-associated pathways. RT-PCR analysis also supported altered TET1 expression in AML samples. The TET1 A256V variant was detected and experimentally validated. Conclusions: This study highlights the somatic mutational landscape of baseline (at diagnosis) and relapsed AML and identifies recurrent driver genes, altered signaling pathways, mutational signatures, and actionable targets with possible therapeutic relevance. The integration of mutational and expression analyses further supports a potential role for TET1 in AML biology, although the functional significance of specific variants such as A256V remains uncertain.
Open AccessIntegrated Genomic Profiling of Newly Diagnosed and Relapsed Acute Myeloid Leukemia Identifies Driver Genes, Mutational Signatures, and Therapeutic Targets
Background/Objectives: Acute myeloid leukemia (AML) is a hematologic malignancy of substantial genetic heterogeneity that exhibits clonal growth and blocked differentiation of myeloid progenitor cells in the bone marrow (BM). Genetic alterations play a vital role in the progression, initiation, and recurrence of AML. The aim of this study was to identify the somatic mutational landscape, pathway perturbations, mutational signatures, and druggability of baseline (at diagnosis) and relapsed AML to determine possible treatment options. Methods: Between 2020 and 2026, 120 diagnostic BM or PB samples were prospectively collected from baseline (at diagnosis) AML patients at AIIMS, New Delhi. WES was conducted of 10 BM samples from five baseline (at diagnosis) and five relapsed patients with AML. Somatic variations were identified by GATK-Mutect2 and annotated by ANNOVAR. Driver genes and pathways were analyzed using Maftools, OncodriveCLUST, and clusterProfiler. Extraction of mutational signatures was performed with the help of SigProfilerExtractor, and evaluation of drug–gene interactions was carried out with the help of DGIdb. In addition, RT-PCR was performed to estimate the expression level of TET1. The recurrent TET1 variation was validated using Sanger sequencing and PCR amplification. Results: Missense mutations were the most common variant type in the cohort, and C > T transitions were the predominant nucleotide substitution pattern. There were recurrent mutations in core AML driver genes, including TET1, FLT3, and TP53, and relapsed samples demonstrated increased involvement and complexity of the signaling system. Pathway analysis revealed widespread dysregulation of carcinogenic networks, including RTK-RAS, WNT, TP53, and PI3K signaling. Mutational signature analysis identified COSMIC SBS5, SBS8, and SBS40, which are associated with mechanisms involving oxidative damage. A large number of actionable targets were identified through druggability screening, particularly involving epigenetic regulators and kinase-associated pathways. RT-PCR analysis also supported altered TET1 expression in AML samples. The TET1 A256V variant was detected and experimentally validated. Conclusions: This study highlights the somatic mutational landscape of baseline (at diagnosis) and relapsed AML and identifies recurrent driver genes, altered signaling pathways, mutational signatures, and actionable targets with possible therapeutic relevance. The integration of mutational and expression analyses further supports a potential role for TET1 in AML biology, although the functional significance of specific variants such as A256V remains uncertain.
- 30 April 2026
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (5) , 1069-1077
Role of Flow Cytometric Enumeration of Circulating hMICL ( CD371 ) Positive Leukemic Stem Cells in Diagnosis and Prognostication of BCR :: ABL1 ‐Negative Myeloproliferative Neoplasms
Background: BCR‐ABL1‐negative myeloproliferative neoplasms (MPNs) often exhibit overlapping clinical and morphological features, making accurate subcategorization challenging. The h‐MICL (CD371) antigen, selectively expressed on leukemic stem cells (LSCs) and absent on CD34 + CD38 − cells in normal or regenerating marrow, represents a potential diagnostic and prognostic marker. Objectives: This study aimed to evaluate the diagnostic utility of circulating CD34 + CD38 − h‐MICL + cells in subtyping BCR‐ABL1‐negative MPNs and to assess their correlation with the Dynamic International Prognostic Scoring System (DIPSS) score. Additionally, to identify a cut‐off value of CD34 + CD38 − h‐MICL + cells that can effectively differentiate PMF. Methods: Fifty‐four patients with BCR‐ABL1‐negative MPNs were prospectively enrolled at a tertiary care center in North India over 18 months. Peripheral blood was analyzed via flow cytometry to quantify CD34 + , CD34 + CD38 + , CD34 + CD38 − , and CD34 + CD38 − h‐MICL + cell subsets. Results: A significant increase in circulating CD34 + CD38 − h‐MICL + cells was observed in patients with overt MF (median 2.8%), prefibrotic MF (4.15%), and post‐PV/ET MF (3%) compared to PV and ET (median 0%; p < 0.001). A threshold of ≥ 0.9% CD34 + CD38 − h‐MICL + cells effectively identified MF cases with 88% sensitivity and 89% specificity. Moreover, a positive correlation was found between the percentage of CD34 + CD38 − h‐MICL + cells and DIPSS score ( ρ = 0.41, p = 0.036), with every 1.72% increase in this cell population corresponding to a 1‐point rise in DIPSS score. Conclusion: Circulating CD34 + CD38 − h‐MICL + cells represent a promising biomarker; their quantification may aid in subclassification, particularly in distinguishing prefibrotic MF from ET, and may serve as a potential target for future therapeutic strategies. Further validation in larger cohorts is warranted.
- 30 April 2026
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (5) , 1069-1077
Role of Flow Cytometric Enumeration of Circulating hMICL ( CD371 ) Positive Leukemic Stem Cells in Diagnosis and Prognostication of BCR :: ABL1 ‐Negative Myeloproliferative Neoplasms
Background: BCR‐ABL1‐negative myeloproliferative neoplasms (MPNs) often exhibit overlapping clinical and morphological features, making accurate subcategorization challenging. The h‐MICL (CD371) antigen, selectively expressed on leukemic stem cells (LSCs) and absent on CD34 + CD38 − cells in normal or regenerating marrow, represents a potential diagnostic and prognostic marker. Objectives: This study aimed to evaluate the diagnostic utility of circulating CD34 + CD38 − h‐MICL + cells in subtyping BCR‐ABL1‐negative MPNs and to assess their correlation with the Dynamic International Prognostic Scoring System (DIPSS) score. Additionally, to identify a cut‐off value of CD34 + CD38 − h‐MICL + cells that can effectively differentiate PMF. Methods: Fifty‐four patients with BCR‐ABL1‐negative MPNs were prospectively enrolled at a tertiary care center in North India over 18 months. Peripheral blood was analyzed via flow cytometry to quantify CD34 + , CD34 + CD38 + , CD34 + CD38 − , and CD34 + CD38 − h‐MICL + cell subsets. Results: A significant increase in circulating CD34 + CD38 − h‐MICL + cells was observed in patients with overt MF (median 2.8%), prefibrotic MF (4.15%), and post‐PV/ET MF (3%) compared to PV and ET (median 0%; p < 0.001). A threshold of ≥ 0.9% CD34 + CD38 − h‐MICL + cells effectively identified MF cases with 88% sensitivity and 89% specificity. Moreover, a positive correlation was found between the percentage of CD34 + CD38 − h‐MICL + cells and DIPSS score ( ρ = 0.41, p = 0.036), with every 1.72% increase in this cell population corresponding to a 1‐point rise in DIPSS score. Conclusion: Circulating CD34 + CD38 − h‐MICL + cells represent a promising biomarker; their quantification may aid in subclassification, particularly in distinguishing prefibrotic MF from ET, and may serve as a potential target for future therapeutic strategies. Further validation in larger cohorts is warranted.
- 16 December 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (2) , 466-469
Reduced CD38 Expression in CD34 Positive Leukemic Myeloid Blasts is Associated With an Adverse Genetic Profile in the Treatment‐Naive Acute Myeloid Leukaemia
- 16 December 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (2) , 466-469
Reduced CD38 Expression in CD34 Positive Leukemic Myeloid Blasts is Associated With an Adverse Genetic Profile in the Treatment‐Naive Acute Myeloid Leukaemia
- 5 December 2025
- Published by Wiley in Transfusion
- Vol. 66 (1) , 8-10
Broken cells and hidden genes: Detection of SLC4A1 variant of hereditary spherocytosis in a blood donor
- 5 December 2025
- Published by Wiley in Transfusion
- Vol. 66 (1) , 8-10
Broken cells and hidden genes: Detection of SLC4A1 variant of hereditary spherocytosis in a blood donor
- 27 October 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-7
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia
- 27 October 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-7
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia
- 16 October 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (4) , 1476-1482
Decoding the Haematological Enigma: Insights from Primary Hypertrophic Osteoarthropathy Case Studies
Primary Hypertrophic Osteoarthropathy (PHO) demonstrates variable inherited penetrance, and clinical expression. The identification of SLCO2A1 (solute carrier organic anion transporter family member 2A1), HPGD(Hydroxyl prostaglandin dehydrogenase) has provided new insights into its pathophysiology. These discoveries have facilitated diagnosis, particularly in paediatric population. This study emphasises genetic level diagnostic approach alongside therapeutic interventions. A prospective, multicentric study was conducted at two tertiary care centre. Eight PHO cases were identified after excluding all other causes of transfusion-dependent microcytic hypochromic anaemia. Genetic mutation in the genes SLCO2A1, HPGD were studied. All patients received treatment with etoricoxib and steroid therapy, were followed up for one year. In our cohort, all were males. Six patients had classical phenotypic expression. Three had prominent gastrointestinal manifestations. Two paediatric patients had family history of transfusion-dependent anaemia. All had homozygous recessive SLCO2A1 mutation. Five patients experienced transient improvement in form of transfusion-free period, decrease in spleen size, and reduced arthralgia, fatigue. Three patients didn’t demonstrate any major therapeutic benefit. Clinicians should maintain high index of suspicion for PHO in young patients presenting with transfusion-dependent microcytic anaemia, particularly after excluding all inherited, acquired causes. Although etoricoxib, steroids show therapeutic promise. Further extensive research is necessary to establish their efficacy, safety.
- 16 October 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (4) , 1476-1482
Decoding the Haematological Enigma: Insights from Primary Hypertrophic Osteoarthropathy Case Studies
Primary Hypertrophic Osteoarthropathy (PHO) demonstrates variable inherited penetrance, and clinical expression. The identification of SLCO2A1 (solute carrier organic anion transporter family member 2A1), HPGD(Hydroxyl prostaglandin dehydrogenase) has provided new insights into its pathophysiology. These discoveries have facilitated diagnosis, particularly in paediatric population. This study emphasises genetic level diagnostic approach alongside therapeutic interventions. A prospective, multicentric study was conducted at two tertiary care centre. Eight PHO cases were identified after excluding all other causes of transfusion-dependent microcytic hypochromic anaemia. Genetic mutation in the genes SLCO2A1, HPGD were studied. All patients received treatment with etoricoxib and steroid therapy, were followed up for one year. In our cohort, all were males. Six patients had classical phenotypic expression. Three had prominent gastrointestinal manifestations. Two paediatric patients had family history of transfusion-dependent anaemia. All had homozygous recessive SLCO2A1 mutation. Five patients experienced transient improvement in form of transfusion-free period, decrease in spleen size, and reduced arthralgia, fatigue. Three patients didn’t demonstrate any major therapeutic benefit. Clinicians should maintain high index of suspicion for PHO in young patients presenting with transfusion-dependent microcytic anaemia, particularly after excluding all inherited, acquired causes. Although etoricoxib, steroids show therapeutic promise. Further extensive research is necessary to establish their efficacy, safety.
- 20 September 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 1061-1064
Sitosterolemia: Unveiling an Underdiagnosed Case Series of Haemolytic Anaemia
Sitosterolemia is a rare autosomal recessive lipid metabolic condition characterized by excessive absorption of plant sterols through the intestinal mucosa, resulting in excessive sterols in the blood. Four patients of age ranging from 10 to 29 years presented to the outpatient department with clinical features of hemolytic anemia without any features of hypercholesterolemia. Peripheral smear examination of all patients showed stomatocytes and macro-thrombocytopenia. Next-generation sequencing revealed mutations in the ABCG5 gene: a homozygous c.727 C > T mutation, compound heterozygous c.1336 C > T and c.1292 C > G mutations in two cases, and homozygous mutation and deletion in the ABCG8 c.1720 G > A and c.408 del in two cases, respectively. Three of them were put on ezetimibe along with a low plant sterol diet and have shown significant hemoglobin improvement; the fourth patient has just started on the same. Our case series highlights a rare but manageable cause of hemolytic anemia suspected from peripheral blood examination, needing molecular genetic diagnosis with good results on proper management.
- 20 September 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 1061-1064
Sitosterolemia: Unveiling an Underdiagnosed Case Series of Haemolytic Anaemia
Sitosterolemia is a rare autosomal recessive lipid metabolic condition characterized by excessive absorption of plant sterols through the intestinal mucosa, resulting in excessive sterols in the blood. Four patients of age ranging from 10 to 29 years presented to the outpatient department with clinical features of hemolytic anemia without any features of hypercholesterolemia. Peripheral smear examination of all patients showed stomatocytes and macro-thrombocytopenia. Next-generation sequencing revealed mutations in the ABCG5 gene: a homozygous c.727 C > T mutation, compound heterozygous c.1336 C > T and c.1292 C > G mutations in two cases, and homozygous mutation and deletion in the ABCG8 c.1720 G > A and c.408 del in two cases, respectively. Three of them were put on ezetimibe along with a low plant sterol diet and have shown significant hemoglobin improvement; the fourth patient has just started on the same. Our case series highlights a rare but manageable cause of hemolytic anemia suspected from peripheral blood examination, needing molecular genetic diagnosis with good results on proper management.